背景:干眼症是一种常见的眼病。人工泪液补充剂广泛用于治疗干眼症。然而,在接受人工泪液长期治疗的患者中观察到多种不良反应,这可能会影响治疗效果。
目的:分析白细胞介素-1β(IL-1β)的特点,白细胞介素-6(IL-6),干眼症患者肿瘤坏死因子-α(TNF-α)水平及人工泪液联合环孢素A的治疗效果。
方法:选取2020年4月至2022年4月西宁市第一人民医院收治的124例干眼症患者作为观察组,同期20例健康个体作为对照组。炎症标志物的水平,包括IL-1β,IL-6和TNF-α,进行了分析。将观察组进一步分为研究组和对照组,每人62名患者。对照组接受人工泪液,而研究组接受了人工泪液和环孢素A的组合。炎症标志物,Schirmer\'stest(SIT),泪液破裂时间(TBUT),角膜荧光素染色(CFS),国家眼科研究所视觉功能问卷-25(NEI-VFQ-25)得分,比较两组患者的不良事件(AE)。
结果:观察组血清IL-1β水平明显升高,IL-6、TNF-α与健康组比较。治疗后,研究组显示IL-1β大幅减少,IL-6和TNF-α水平相对于对照组。此外,治疗后,与对照组相比,研究组的CFS评分显著降低,SIT和BUT水平均显著升高.此外,在干眼症的主要症状和畏光等继发性症状中观察到显着改善,异物感,疲劳,红眼,以及研究组内的灼烧感。此外,研究组治疗后NEI-VFQ-25各维度评分均显著高于对照组(P<0.05).值得注意的是,在整个治疗期间,两组均报告了显著的AE。
结论:环孢素A联合人工泪液治疗干眼症有效,通过提高SIT和TBUT水平来提高结果,降低CFS分数,改善与视觉相关的生活质量。
BACKGROUND: Dry eye is a common eye disease. Artificial tears supplements are widely used for the treatment of dry eyes. However, multiple adverse effects have been observed in patients receiving long-term treatment with artificial tears, which may affect the therapeutic effect.
OBJECTIVE: To analyze the characteristics of interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α) levels in patients with dry eye and the therapeutic effect of artificial tears combined with cyclosporine A.
METHODS: A total of 124 dry eye patients treated at The First People\'s Hospital of Xining from April 2020 to April 2022 were selected as the observation group, while 20 healthy individuals served as the control group during the same period. Levels of inflammatory markers, including IL-1β, IL-6, and TNF-α, were analyzed. The observation group was further divided into a study group and a control group, each consisting of 62 patients. The control group received artificial tears, whereas the study group received a combination of artificial tears and cyclosporine A. Inflammatory markers, Schirmer\'s test (SIT), tear break-up time (TBUT), corneal fluorescein staining (CFS), National Eye Institute Visual Function Questionnaire-25 (NEI-VFQ-25) scores, and adverse events (AEs) were compared between the two groups.
RESULTS: The observation group exhibited significantly elevated serum levels of IL-1β, IL-6, and TNF-α in comparison to the healthy group. Following treatment, the study group demonstrated substantial reductions in IL-1β, IL-6, and TNF-α levels relative to the control group. Moreover, after treatment, the study group experienced a marked decrease in CFS scores and significant increases in both SIT and BUT levels when compared to the control group. Additionally, significant improvements were observed in the primary symptom of dry eye and secondary symptoms such as photophobia, foreign body sensation, fatigue, red eye, and burning sensation within the study group. Furthermore, post-treatment NEI-VFQ-25 scores across all dimensions exhibited significant enhancements in the study group compared to the control group (P < 0.05). It is noteworthy that significant AEs were reported in both groups throughout the treatment period.
CONCLUSIONS: Cyclosporine A combined with artificial tears is effective in treating dry eye, yielding enhanced outcomes by improving SIT and TBUT levels, reducing CFS scores, and ameliorating vision-related quality of life.